Drugs / AVP-21D9
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01202695 | Aug 2010 → Jun 2011 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2010-11-04 | Emergent BioSolutions | Regulatory Emergent BioSolutions Receives Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax emergentbiosolutions.com ↗
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its fully human anthrax monoclonal antibody AVP-21D9, which is in development for the treatment of inhalation anthrax, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). |
| 2010-10-01 | Emergent BioSolutions | Regulatory Emergent BioSolutions Receives Fast Track Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalational Anthrax emergentbiosolutions.com ↗
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-11-04 | Emergent BioSolutions | Emergent BioSolutions Receives Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax emergentbiosolutions.com ↗ |
| 2010-10-01 | Emergent BioSolutions | Emergent BioSolutions Receives Fast Track Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalational Anthrax emergentbiosolutions.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVP-21D9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01202695 ↗ |
| Known as | Thravixa | “An anthrax antitoxin, AVP-21D9, also known as Thravixa (fully human anthrax monoclonal antibody), is being developed as a therapeutic agent against anthrax toxemia.” PMID 24733473 ↗ Apr 2014 |
| Modality | Monoclonal antibody | “fully human anthrax monoclonal antibody” PMID 24733473 ↗ Apr 2014 |
| Route | Intravenous | “intravenously, single dose” NCT01202695 ↗ |